Cdk2 Inhibitor II,
MLS001174919,
CHEMBL411491,
222035-13-4,
SMR000592222,
4-[2-(5-bromo-2-oxoindol-3-yl)hydrazinyl]benzenesulfonamide,
AC1NYLC3,
Oxindole-Based Inhibitor 16,
BDBM7680,
CHEMBL1532112,
SCHEMBL15317870,
BDBM69898,
cid_5858639,
CTK8F8507,
HMS2890M19,
HMS3229D07,
BDBM50202299,
IN1383,
AKOS034451308,
ZINC100375608,
J-014585,
Z56762940,
4-[(5-bromo-2-oxo-3-indolyl)hydrazo]benzenesulfonamide,
4-[2-(5-Bromo-2-oxoindoline-3-ylidene)hydrazino]benzenesulfonamide,
4-[N''-(5-bromo-2-keto-indol-3-yl)hydrazino]benzenesulfonamide,
4-[2-(5-bromanyl-2-oxidanylidene-indol-3-yl)hydrazinyl]benzenesulfonamide,
4-[2-(5-bromo-2-hydroxy-3H-indol-3-ylidene)hydrazin-1-yl]benzene-1-sulfonamide,
4-[2-(5-Bromo-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-hydrazino]benzenesulfonamide,
4-{2-[(3Z)-5-bromo-2-oxo-2,3-dihydro-1H-indol-3-ylidene]hydrazin-1-yl}benzene-1-sulfonamide,
Compound 3,
D0P3RF,
ZINC05258402,
CID5858639,